981 related items for PubMed ID: 30337183
1. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[Abstract] [Full Text] [Related]
2. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators.
Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251
[Abstract] [Full Text] [Related]
3. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
Iio K, Morikawa Y, Miyata K, Kaneko T, Misawa M, Yamagishi H, Miura M.
J Pediatr; 2022 Jan 28; 240():158-163.e4. PubMed ID: 34461064
[Abstract] [Full Text] [Related]
4. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A, KAICA trial Investigators.
Lancet; 2019 Mar 16; 393(10176):1128-1137. PubMed ID: 30853151
[Abstract] [Full Text] [Related]
5. Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.
Miyata K, Miura M, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H.
Circ Cardiovasc Qual Outcomes; 2021 Feb 16; 14(2):e007191. PubMed ID: 33541111
[Abstract] [Full Text] [Related]
6. Intravenous immunoglobulin for the treatment of Kawasaki disease.
Broderick C, Kobayashi S, Suto M, Ito S, Kobayashi T.
Cochrane Database Syst Rev; 2023 Jan 25; 1(1):CD014884. PubMed ID: 36695415
[Abstract] [Full Text] [Related]
7. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
Nakagama Y, Inuzuka R, Hayashi T, Shindo T, Hirata Y, Shimizu N, Inatomi J, Yokoyama Y, Namai Y, Oda Y, Takamizawa M, Harita Y, Oka A.
Pediatr Int; 2016 Mar 25; 58(3):180-184. PubMed ID: 26222760
[Abstract] [Full Text] [Related]
8. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
Lancet Child Adolesc Health; 2021 Dec 25; 5(12):852-861. PubMed ID: 34715057
[Abstract] [Full Text] [Related]
9. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec 25; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
10. Bradycardia Associated with Prednisolone in Children with Severe Kawasaki Disease.
Nagakura A, Morikawa Y, Sakakibara H, Miura M.
J Pediatr; 2017 Jun 25; 185():106-111.e1. PubMed ID: 28343657
[Abstract] [Full Text] [Related]
11. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
Jibiki T, Kato I, Shiohama T, Abe K, Anzai S, Takeda N, Yamaguchi KI, Kanazawa M, Kurosaki T.
Pediatr Int; 2011 Oct 25; 53(5):729-735. PubMed ID: 21342358
[Abstract] [Full Text] [Related]
12. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
[Abstract] [Full Text] [Related]
13. High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.
Goto M, Miyagawa N, Kikunaga K, Miura M, Hasegawa Y.
Endocr J; 2015 Jul 06; 62(2):145-51. PubMed ID: 25342092
[Abstract] [Full Text] [Related]
14. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S, Kimura M, Ishikawa T, Ohzeki T.
Clin Drug Investig; 2011 Jul 06; 31(3):191-9. PubMed ID: 21456105
[Abstract] [Full Text] [Related]
15. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
Kobayashi T, Inoue Y, Otani T, Morikawa A, Kobayashi T, Takeuchi K, Saji T, Sonobe T, Ogawa S, Miura M, Arakawa H.
Pediatr Infect Dis J; 2009 Jun 06; 28(6):498-502. PubMed ID: 19504733
[Abstract] [Full Text] [Related]
16. Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.
Yoshikane Y, Okuma Y, Miyamoto T, Hashimoto J, Fukazawa R, Kato T, Takeda A, Suda K, Matsushita T, Hiroe M, Imanaka-Yoshida K.
Pediatr Rheumatol Online J; 2021 Jun 05; 19(1):82. PubMed ID: 34090475
[Abstract] [Full Text] [Related]
17. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
Hashino K, Ishii M, Iemura M, Akagi T, Kato H.
Pediatr Int; 2001 Jun 05; 43(3):211-7. PubMed ID: 11380911
[Abstract] [Full Text] [Related]
18. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
Lim YJ, Jung JW.
Yonsei Med J; 2014 Sep 05; 55(5):1260-6. PubMed ID: 25048483
[Abstract] [Full Text] [Related]
19. Role of glucocorticoids in Kawasaki disease.
Miura M.
Int J Rheum Dis; 2018 Jan 05; 21(1):70-75. PubMed ID: 29105310
[Abstract] [Full Text] [Related]
20. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
